BioFM Platform
AI drug discovery platform
Enables scalable molecular design and target biology discovery in a way that is reliable, reproducible and correct.
Learn more
Deep Genomics
AIToronto, ON
Uses an AI foundation-model platform (BioFM, including the BigRNA model) to discover and design RNA and genetic-medicine drug candidates.
Canadian innovation builds a brighter tomorrow.
About
Company site: deepgenomics.comUses an AI foundation-model platform (BioFM, including the BigRNA model) to discover and design RNA and genetic-medicine drug candidates.
Raised $180M Series C financing led by SoftBank Vision Fund 2, with CPP Investments and Fidelity among participants (July 2021). deepgenomics.com
Entered a preclinical collaboration with BioMarin Pharmaceutical to identify oligonucleotide drug candidates across four rare-disease indications (November 2020). deepgenomics.com
Nominated DG12P1, described as the industry's first AI-discovered therapeutic candidate, targeting Wilson disease (September 2019). deepgenomics.com
Introduced BigRNA, a roughly 2-billion-parameter transformer foundation model for RNA biology and therapeutic discovery (September 2023). deepgenomics.com
Products & Services
Company site: deepgenomics.comProducts Deep Genomics publishes on its own site. Each card links to the page it was taken from.
Funding & Investors
Announced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Series C ($180M)
Jul 28, 2021
Undiscloseddeepgenomics.comInvestors: SoftBank Vision Fund 2, CPP Investments, Fidelity Management & Research Company, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, True Ventures
Series B ($40M)
Jan 7, 2020
Undiscloseddeepgenomics.comInvestors: Future Ventures, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, True Ventures
Venture round
Sep 25, 2017
US$13.0Mdeepgenomics.comInvestors: Khosla Ventures, True Ventures
Total disclosed: US$13.0MLatest: Series C ($180M) · Jul 28, 2021
Partnerships
Publicly announced partnerships.
BioMarin Pharmaceutical
Preclinical collaboration using Deep Genomics' AI Workbench to identify oligonucleotide drug candidates across four rare disease indications (2020).
Wave Life Sciences
Collaboration to identify splicing-related therapeutic targets for genetic neuromuscular disorders using Deep Genomics' ML platform (2018).
Mila
Talent collaboration: Deep Genomics joined the Mila community to recruit AI, software engineering and RNA biology talent (2021).
People
Sourced from the company's own pages or announcements.
Brian O'Callaghan
Chief Executive Officer
Brendan Frey
Founder & Chief Innovation Officer
Similar Companies
Other companies in AI.
